Abstract
IC children <2 yrs represent a group at increased risk of invasive HITB infection. PRP-D conjugate vaccine (Connaught) was administered IM to 9 IC children aged 2-23 mo to assess their antibody response. Three had solid tumors (1 hepatoblastoma, 1 Wilm's, 1 neuroblastoma), 3 had sickle cell disease, 1 had AML, 1 had ALL and 1 was on immunosuppressive therapy post hepatic transplant. All cancer patients were in remission. There were no serious side effects following vaccine administration, and no children have had documented HITB infection to date. Pre and 1 mo post vaccine HITB antibody levels were measured by RIA; mean pre vaccine level was 0.025 μg/ml (range <0.012-0.12), and mean post vaccine level was O.460 μg/ml (range <0.012-1.89). Only 2/9. children achieved a protective titer ( >1 μg/ml). Of the non-responders, 4/7 were >18 mo. Three children, 16-21 mo, received a 2nd vaccine dose 1 mo after the first, and 1 responded. These data provide preliminary information regarding the response of IC children <2 yrs to PRP-D conjugate vaccine and indicate that IC children 18-23 mo do not reliably respond to a single dose of vaccine.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tristram, D., McMillan, J., Weiner, L. et al. ANTIBODY RESPONSE TO HEMOPHILUS INFLUENZAE, TYPE B (HITS) PRP-D CONJUGATE VACCINE IN IMMUNOCOMPROMISED (IC) PATIENTS <2 YEARS OF AGE. Pediatr Res 21 (Suppl 4), 336 (1987). https://doi.org/10.1203/00006450-198704010-01015
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-01015